An Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor in Patients with Advanced Solid Tumors

Project: Research

Project Details

Effective start/end date18/06/2117/06/26


  • treatment safety
  • treatment efficacy
  • solid tumors
  • Pharmacokinetics